Key points from article :
Report looks at disrupting influence of longevity across markets.
Buck Institute is focussed on genes that affect healthspan and lifespan.
It's CEO, Eric Verdin, explains why biomarkers are critical to ageing research.
Joan Mannick (resTORbio) and Steven Braithwaite (Alkahest) discuss other challenges.
Early human trials will help to improve trial designs.
We see increased heterogeneity as patients get older.
Easier to demonstrate that a therapeutic can treat rather than prevent a disease.
Angela Tyrell (Longevity Leaders SVP) looks at trends in the wellgevity market.
Includes digital tracking, consumer testing, diet and mental health.
Jackie Marshall Cyrus talks about wellbeing in later life.
Healthcare professionals often ignore the sexuality of adults past a completely subjective age range.
